El Cerrito, CA, United States of America

Raquel Orozco

USPTO Granted Patents = 8 

Average Co-Inventor Count = 4.8

ph-index = 2

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 2019-2025

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Raquel Orozco: Pioneering Innovations in Viral Inactivation

Introduction

Raquel Orozco, an accomplished inventor based in El Cerrito, California, has made significant contributions to the field of viral inactivation with a total of seven patents to her name. Her work focuses on developing methods that enhance the safety and efficiency of protein manufacture by effectively inactivating viruses.

Latest Patents

Orozco's latest patents include innovative methods for continuously inactivating a virus during the manufacture of proteins. These methodologies involve combining a protein composition with a virus-inactivation reagent at a predetermined volumetric ratio to create a treatment composition. This process allows for the maintenance of specific properties across a range of protein concentrations, without requiring feedback control. Additionally, she has developed a system to determine critical process parameters for a continuous viral inactivation reactor, showcasing her commitment to advancing the technology in this vital area.

Career Highlights

Raquel Orozco is currently affiliated with Boehringer Ingelheim International GmbH, where she continues to drive innovations in viral inactivation technologies. Her expertise in process design and her ability to create effective solutions for complex challenges in protein manufacture have established her as a respected figure in her field.

Collaborations

During her career, Orozco has collaborated with notable colleagues, including Jonathan Coffman and Marcus Andre Fiadeiro. This collaborative spirit has been pivotal in fostering an environment of innovation and enhanced research output within her team.

Conclusion

Raquel Orozco stands out as an influential inventor whose work has considerably impacted viral inactivation processes in protein manufacture. With her extensive patent portfolio and dedication to innovation, she continues to pave the way for safer biological manufacturing practices.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…